Brian Wheeler Quoted on Dealmaking in GP-led Secondaries Market
11 December 2024
Pitchbook
Foley & Lardner LLP partner Brian Wheeler commented in the Pitchbook article, “GP-led secondaries to end 2024 with new record,” assessing the prospects for dealmaking in the space heading into 2025.
“I think [secondaries] will continue to grow, but it’s still just scratching the surface of the liquidity that’s really needed,” Wheeler explained, adding that some private equity firms lack sufficient personnel to improve the operations of their portfolio companies and prefer to sell those assets to realize returns for investors.
“There are NAV loans; there are secondary funds or LP-led exits—but you still have a huge backlog of companies looking to exit,” Wheeler added.
People
Related News
13 December 2024
In the News
Brian Tomkins Featured Across Legal Press for Arrival to Foley
Foley & Lardner LLP partner Brian Tomkins is featured across legal press for his recent arrival to the firm.
11 December 2024
In the News
Nathan Beaver Discusses GLP-1 Compounding, FDA Deliberations
Foley & Lardner LLP partner Nathan Beaver discussed the ongoing deliberations at the U.S. Food and Drug Administration over a popular class of drugs in the PharmaVoice article, "GLP-1 compounding is still in limbo. Will the FDA leave it for the next administration?"
11 December 2024
In the News
David Rosen Discusses Health Care and Life Sciences Sector Focuses in 2025
Foley & Lardner LLP partner David Rosen shared insight on what the health care and life sciences sector is focused on in the lead up to the new year in the Law360 article, "What We Learned About Life Sciences Asset Class In 2024."